Zynerba Pharmaceuticals Presents Data on Zygel™ at the 55th | ZYNE Stock News
Zygel - Zynerba
Shares of Devon-Based Zynerba Pharmaceuticals Surge After Firm Wins Patent
Zynerba Pharmaceuticals, Inc. General Corporate Statement (Form8) - Zynerba Pharmaceuticals (NASDAQ:ZYNE) - Benzinga
Zynerba Pharma Receives FDA Guidance For Phase 3 Trial Of Zygel; Street Sees 75% Upside
Zynerba: Transdermal Cannabinoids Have Significant Potential (NASDAQ:ZYNE) | Seeking Alpha
EDGAR Filing Documents for 0001104659-22-128854
Zynerba Pharmaceuticals Inc receives guidance from the US Food and Drug Administration on a confirmatory Phase 3 trial of Zygel in patients with Fragile X syndrome
Zynerba Pharmaceuticals Inc updates on its meeting with the US Food and Drug Administration regarding its Fragile X syndrome program using Zygel
Zynerba Pharmaceuticals CEO welcomes FDA approval of cannabinoid products
Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome
Stan Banks - Director of CMC and Product Development - Zynerba Pharmaceuticals | LinkedIn
g260361mmi021.gif
Zynerba Synthetic CBD Gel for Epilepsy Proves Safe but Not Effective in FDA Phase 2 Trial – New Cannabis Ventures
FDA urged to approve Sarepta DMD drug by dozens of medical experts - STAT
Zynerba: Repeated Trial Failures, Some Post Hoc Success (NASDAQ:ZYNE) | Seeking Alpha
Big medical bet: Why this Philly area pharma company's shares jumped 65 percent in a week
SCYNEXIS Inc names Zynerba Pharmaceuticals Inc CEO Armando Anido to its board
Zynerba Pharmaceuticals Inc's CBD skin gel Zygel offers a potential goldmine of therapies for Fragile X syndrome, and other conditions
